
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
16 November 2021
Charities call on NHS to treat blood cancer equally in decision-making
The Blood Cancer Alliance undertook an evidence review to inform a new report exploring the unmet needs of people with blood cancer across the UK.
19 September 2023
“Fundraising never tasted so good!”: Star-studded evening raises over £235,000 for life-saving leukaemia research
Chefs and celebrities mingled at The Dorchester last night for a gastronomic spectacular in aid of Leukaemia UK, raising over £235,000 to support world-class research into the devastating disease. Who’s…
30 March 2022
One Cancer Voice 10-Year Cancer Plan Consensus Statement
We have joined with 53 cancer charities to speak with One Cancer Voice and publish 10 tests that the Government’s new 10-year Cancer Plan must meet if it is to be successful.
9 May 2018
Sharing this exciting news: a treatment advance for childhood leukaemia
A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades